Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer

Ryuichi Suemitsu, Ichiro Yoshino, Makiko Tomiyasu, Seiichi Fukuyama, Tatsuro Okamoto, Yoshihiko Maehara

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose. In view of the increasing number of patients diagnosed with lung cancer every year worldwide, there is an urgent need for an effective screening marker to improve its early detection. Methods. We quantified the level of immunoreactive proteins for the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in the sera of 54 patients with non-small cell lung cancer (NSCLC) and 25 healthy control subjects, by using enzyme-linked immunosorbent assays with specific monoclonal antibodies. Results. The TIMP-1 level was significantly higher, and the TIMP-2 level was significantly lower in the patients with NSCLC than in the controls. Furthermore, both TIMP-1 and TIMP-2 were significantly higher in patients with squamous cell carcinoma than in those with adenocarcinoma. The TIMP-1 level in patients with stage III/IV disease was significantly higher than that in those with stage I/II disease. The TIMP-1/TIMP-2 ratio was significantly higher in the patients with NSCLC, and the receiver-operating characteristic curves analysis revealed that the TIMP-1/2 ratio, but not TIMP-1 or -2 alone, was a better screening marker for NSCLC than carcinoembryonic antigen (P < 0.0001). Patients with a high TIMP-1 value had significantly shorter disease-free survival (P = 0.0479), but those with a high TIMP-1/2 ratio did not. Conclusion. The TIMP-1/2 ratio may be a good screening marker of NSCLC; however, it was less effective than TIMP-1 as a prognostic factor.

Original languageEnglish
Pages (from-to)896-901
Number of pages6
JournalSurgery today
Volume34
Issue number11
DOIs
Publication statusPublished - Nov 1 2004

Fingerprint

Tissue Inhibitor of Metalloproteinase-2
Tissue Inhibitor of Metalloproteinase-1
Non-Small Cell Lung Carcinoma
Serum
Carcinoembryonic Antigen
ROC Curve
Disease-Free Survival
Squamous Cell Carcinoma
Lung Neoplasms
Healthy Volunteers
Adenocarcinoma
Enzyme-Linked Immunosorbent Assay
Monoclonal Antibodies

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Suemitsu, R., Yoshino, I., Tomiyasu, M., Fukuyama, S., Okamoto, T., & Maehara, Y. (2004). Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer. Surgery today, 34(11), 896-901. https://doi.org/10.1007/s00595-004-2853-y

Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer. / Suemitsu, Ryuichi; Yoshino, Ichiro; Tomiyasu, Makiko; Fukuyama, Seiichi; Okamoto, Tatsuro; Maehara, Yoshihiko.

In: Surgery today, Vol. 34, No. 11, 01.11.2004, p. 896-901.

Research output: Contribution to journalArticle

Suemitsu, R, Yoshino, I, Tomiyasu, M, Fukuyama, S, Okamoto, T & Maehara, Y 2004, 'Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer', Surgery today, vol. 34, no. 11, pp. 896-901. https://doi.org/10.1007/s00595-004-2853-y
Suemitsu, Ryuichi ; Yoshino, Ichiro ; Tomiyasu, Makiko ; Fukuyama, Seiichi ; Okamoto, Tatsuro ; Maehara, Yoshihiko. / Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer. In: Surgery today. 2004 ; Vol. 34, No. 11. pp. 896-901.
@article{508603fac6a44c5dbb7773fc56ce92b9,
title = "Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer",
abstract = "Purpose. In view of the increasing number of patients diagnosed with lung cancer every year worldwide, there is an urgent need for an effective screening marker to improve its early detection. Methods. We quantified the level of immunoreactive proteins for the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in the sera of 54 patients with non-small cell lung cancer (NSCLC) and 25 healthy control subjects, by using enzyme-linked immunosorbent assays with specific monoclonal antibodies. Results. The TIMP-1 level was significantly higher, and the TIMP-2 level was significantly lower in the patients with NSCLC than in the controls. Furthermore, both TIMP-1 and TIMP-2 were significantly higher in patients with squamous cell carcinoma than in those with adenocarcinoma. The TIMP-1 level in patients with stage III/IV disease was significantly higher than that in those with stage I/II disease. The TIMP-1/TIMP-2 ratio was significantly higher in the patients with NSCLC, and the receiver-operating characteristic curves analysis revealed that the TIMP-1/2 ratio, but not TIMP-1 or -2 alone, was a better screening marker for NSCLC than carcinoembryonic antigen (P < 0.0001). Patients with a high TIMP-1 value had significantly shorter disease-free survival (P = 0.0479), but those with a high TIMP-1/2 ratio did not. Conclusion. The TIMP-1/2 ratio may be a good screening marker of NSCLC; however, it was less effective than TIMP-1 as a prognostic factor.",
author = "Ryuichi Suemitsu and Ichiro Yoshino and Makiko Tomiyasu and Seiichi Fukuyama and Tatsuro Okamoto and Yoshihiko Maehara",
year = "2004",
month = "11",
day = "1",
doi = "10.1007/s00595-004-2853-y",
language = "English",
volume = "34",
pages = "896--901",
journal = "Surgery Today",
issn = "0941-1291",
publisher = "Springer Japan",
number = "11",

}

TY - JOUR

T1 - Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer

AU - Suemitsu, Ryuichi

AU - Yoshino, Ichiro

AU - Tomiyasu, Makiko

AU - Fukuyama, Seiichi

AU - Okamoto, Tatsuro

AU - Maehara, Yoshihiko

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Purpose. In view of the increasing number of patients diagnosed with lung cancer every year worldwide, there is an urgent need for an effective screening marker to improve its early detection. Methods. We quantified the level of immunoreactive proteins for the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in the sera of 54 patients with non-small cell lung cancer (NSCLC) and 25 healthy control subjects, by using enzyme-linked immunosorbent assays with specific monoclonal antibodies. Results. The TIMP-1 level was significantly higher, and the TIMP-2 level was significantly lower in the patients with NSCLC than in the controls. Furthermore, both TIMP-1 and TIMP-2 were significantly higher in patients with squamous cell carcinoma than in those with adenocarcinoma. The TIMP-1 level in patients with stage III/IV disease was significantly higher than that in those with stage I/II disease. The TIMP-1/TIMP-2 ratio was significantly higher in the patients with NSCLC, and the receiver-operating characteristic curves analysis revealed that the TIMP-1/2 ratio, but not TIMP-1 or -2 alone, was a better screening marker for NSCLC than carcinoembryonic antigen (P < 0.0001). Patients with a high TIMP-1 value had significantly shorter disease-free survival (P = 0.0479), but those with a high TIMP-1/2 ratio did not. Conclusion. The TIMP-1/2 ratio may be a good screening marker of NSCLC; however, it was less effective than TIMP-1 as a prognostic factor.

AB - Purpose. In view of the increasing number of patients diagnosed with lung cancer every year worldwide, there is an urgent need for an effective screening marker to improve its early detection. Methods. We quantified the level of immunoreactive proteins for the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in the sera of 54 patients with non-small cell lung cancer (NSCLC) and 25 healthy control subjects, by using enzyme-linked immunosorbent assays with specific monoclonal antibodies. Results. The TIMP-1 level was significantly higher, and the TIMP-2 level was significantly lower in the patients with NSCLC than in the controls. Furthermore, both TIMP-1 and TIMP-2 were significantly higher in patients with squamous cell carcinoma than in those with adenocarcinoma. The TIMP-1 level in patients with stage III/IV disease was significantly higher than that in those with stage I/II disease. The TIMP-1/TIMP-2 ratio was significantly higher in the patients with NSCLC, and the receiver-operating characteristic curves analysis revealed that the TIMP-1/2 ratio, but not TIMP-1 or -2 alone, was a better screening marker for NSCLC than carcinoembryonic antigen (P < 0.0001). Patients with a high TIMP-1 value had significantly shorter disease-free survival (P = 0.0479), but those with a high TIMP-1/2 ratio did not. Conclusion. The TIMP-1/2 ratio may be a good screening marker of NSCLC; however, it was less effective than TIMP-1 as a prognostic factor.

UR - http://www.scopus.com/inward/record.url?scp=14744275382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14744275382&partnerID=8YFLogxK

U2 - 10.1007/s00595-004-2853-y

DO - 10.1007/s00595-004-2853-y

M3 - Article

C2 - 15526122

AN - SCOPUS:14744275382

VL - 34

SP - 896

EP - 901

JO - Surgery Today

JF - Surgery Today

SN - 0941-1291

IS - 11

ER -